<TABLE> <S> <C>

<ARTICLE>                     5
<LEGEND>
THIS  SCHEDULE  CONTAINS  SUMMARY  FINANCIAL   INFORMATION  EXTRACTED  FROM  THE
UNAUDITED   CONDENSED   CONSOLIDATED   FINANCIAL   STATEMENTS  INCLUDED  IN  THE
REGISTRANT'S  FORM 10-Q FOR THE PERIOD ENDED SEPTEMBER 30, 2000 AND IS QUALIFIED
IN ITS ENTIRETY BY REFERENCE TO SUCH FORM 10-Q.
</LEGEND>
<CIK>                         0001012270
<NAME>                        CollaGenex Pharmaceuticals, Inc.
<MULTIPLIER>                                   1,000
<CURRENCY>                                     U.S. Dollars

<S>                             <C>
<PERIOD-TYPE>                                  9-Mos
<FISCAL-YEAR-END>                              Dec-31-2000
<PERIOD-START>                                 Jan-01-2000
<PERIOD-END>                                   Sep-30-2000
<EXCHANGE-RATE>                                1
<CASH>                                         5,220
<SECURITIES>                                   2,972
<RECEIVABLES>                                  2,954
<ALLOWANCES>                                   373
<INVENTORY>                                    748
<CURRENT-ASSETS>                               12,622
<PP&E>                                         1,143
<DEPRECIATION>                                 437
<TOTAL-ASSETS>                                 13,355
<CURRENT-LIABILITIES>                          5,428
<BONDS>                                        0
                          0
                                    2
<COMMON>                                       88
<OTHER-SE>                                     7,772
<TOTAL-LIABILITY-AND-EQUITY>                   13,355
<SALES>                                        15,485
<TOTAL-REVENUES>                               18,325
<CGS>                                          3,113
<TOTAL-COSTS>                                  25,002
<OTHER-EXPENSES>                               0
<LOSS-PROVISION>                               0
<INTEREST-EXPENSE>                             12
<INCOME-PRETAX>                                (6,190)
<INCOME-TAX>                                   0
<INCOME-CONTINUING>                            (6,190)
<DISCONTINUED>                                 0
<EXTRAORDINARY>                                0
<CHANGES>                                      0
<NET-INCOME>                                   (6,190)
<EPS-BASIC>                                    (0.86)
<EPS-DILUTED>                                  (0.86)


</TABLE>



© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission